Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) Other Non Operating Income (2017 - 2026)

Cogent Biosciences' Other Non Operating Income history spans 10 years, with the latest figure at -$140000.0 for Q1 2026.

  • Quarterly Other Non Operating Income fell 2700.0% to -$140000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$155000.0 through Mar 2026, down 3775.0% year-over-year, with the annual reading at -$20000.0 for FY2025, N/A changed from the prior year.
  • Other Non Operating Income came in at -$140000.0 for Q1 2026, down from -$6000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $682000.0 in Q1 2023 to a low of -$950000.0 in Q4 2023.
  • The 5-year median for Other Non Operating Income is $0.0 (2024), against an average of $130562.5.
  • Year-over-year, Other Non Operating Income skyrocketed 95.37% in 2024 and then plummeted 2700.0% in 2026.
  • Cogent Biosciences' Other Non Operating Income stood at $657000.0 in 2022, then tumbled by 244.6% to -$950000.0 in 2023, then surged by 95.37% to -$44000.0 in 2024, then skyrocketed by 86.36% to -$6000.0 in 2025, then plummeted by 2233.33% to -$140000.0 in 2026.
  • Per Business Quant, the three most recent readings for COGT's Other Non Operating Income are -$140000.0 (Q1 2026), -$6000.0 (Q4 2025), and -$3000.0 (Q3 2025).